BioXcel Therapeutics (BTAI) Operating Expenses (2017 - 2026)

BioXcel Therapeutics' Operating Expenses history runs 10 years deep, the most recent figure standing at $10.4 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 1.58% year-over-year to $10.4 million; the TTM figure through Mar 2026 stood at $51.3 million (down 6.85% YoY), while the FY2025 annual figure was $51.1 million, down 26.48% from the prior year.
• Operating Expenses was $10.4 million for Q1 2026 at BioXcel Therapeutics, down from $10.5 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $53.1 million in Q4 2022 to a low of $10.3 million in Q1 2025.
• Historically, Operating Expenses has averaged $27.3 million across 5 years, with a median of $20.3 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Operating Expenses surged 103.33% in 2022, then slumped 68.12% in 2024.
• A 5-year view of Operating Expenses shows it stood at $53.1 million in 2022, then plunged by 61.89% to $20.3 million in 2023, then sank by 46.38% to $10.9 million in 2024, then declined by 2.96% to $10.5 million in 2025, then dropped by 1.03% to $10.4 million in 2026.
• The last three Operating Expenses figures came in at $10.4 million (Q1 2026), $10.5 million (Q4 2025), and $14.3 million (Q3 2025), per Business Quant data.